Esophageal Cancer Clinical Trials in Boston, Massachusetts
9 recruitingBoston, Massachusetts
Showing 1–9 of 9 trials
Recruiting
Phase 3
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Esophageal CancerGastric Cancer (GC)Gastroesophageal Junction
SOFIE200 enrolled10 locationsNCT07217704
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled258 locationsNCT07431281
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Not Applicable
Resilience and Equity in Aging, Cancer, and Health (REACH)
Esophageal CancerPancreatic CancerGastric Cancer+3 more
Dana-Farber Cancer Institute257 enrolled1 locationNCT04674267
Recruiting
Phase 2
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Esophageal CancerGastric AdenocarcinomaHER2 Gene Mutation
Memorial Sloan Kettering Cancer Center49 enrolled10 locationsNCT06123338
Recruiting
Not Applicable
Serial MRI Scans During Radiation Therapy
Esophageal CancerProstate CancerMRI+5 more
Dana-Farber Cancer Institute149 enrolled2 locationsNCT04188535
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
ModeX Therapeutics, An OPKO Health Company115 enrolled6 locationsNCT06239194